<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03743181</url>
  </required_header>
  <id_info>
    <org_study_id>156</org_study_id>
    <nct_id>NCT03743181</nct_id>
  </id_info>
  <brief_title>Impact of Clinical Pharmacy Services Provided for Patients With Active Rheumatoid Arthritis</brief_title>
  <official_title>Impact of Clinical Pharmacy Services Provided for Patients With Active Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>hager omar mohammed siddik</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Enrolment of clinical pharmacy services in RA patients as a part of health care system has
      been investigated at many studies but not investigated in active RA patients before. This
      study aimed to detect drug therapy-related problems (DTRPs) in active rheumatoid arthritis
      (RA) patients and Investigate the impact of clinical pharmacist interventions on the patient
      clinical outcome and quality of life (QoL). Methods:Prospective, randomized controlled study
      to be carried out at rheumatology outpatient clinic, Ain Shams University Hospitals on 50
      patients with active RA for 6 months.determine if any drug therapy problems are
      present.Develop a plan of care that includes interventions to resolve drug therapy problems,
      achieve goals of therapy, and prevent drug therapy problems. questionnaires was used to
      measure functional status in RA patients using health assessment questionnaire (HAQ) and
      assess self-reported quality of life in patients with (RA) using rheumatoid arthritis quality
      of life questionnaire (RAQOL) and measure adherence using the 4-item Morisky Green Levine
      Medication Adherence Scale and Disease Activity Score-28 was used as an objective method to
      assess RA disease activity.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 14, 2018</start_date>
  <completion_date type="Actual">December 18, 2019</completion_date>
  <primary_completion_date type="Actual">October 10, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>disease activity score</measure>
    <time_frame>6 months</time_frame>
    <description>disease activity score-28 (DAS-28) for measuring disease activity in rheumatoid arthritis patients</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life questionnaire</measure>
    <time_frame>6 months</time_frame>
    <description>Rheumatoid arthritis quality of life questionnaire (RAQOL) for measuring quality of life</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Health assessment questionnaire</measure>
    <time_frame>6 months</time_frame>
    <description>Health assessment questionnaire (HAQ) for measuring functional status in rheumatoid arthritis patients</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">54</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>intervention</arm_group_label>
    <description>will be supplied by pharmaceutical care services provided by the clinical pharmacist plus standard care by physician in attendance.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <description>will received standard care by physician in attendance</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmaceutical care services</intervention_name>
    <description>detection of drug therapy problems and investigation of the impact of clinical pharmacist interventions on the patient clinical outcome and quality of life</description>
    <arm_group_label>intervention</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        rheumatoid arthritis patients from outpatient clinics - Ain shams university hospitals
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 18-60 years old

          -  fulfillment of the American College of Rheumatology /European league against
             rheumatism (2010 ACR/EULAR ) diagnostic criteria for RA.

          -  patients with active RA(defined by DAS28 score &lt; 5.1)

        Exclusion Criteria:

          -  Patients with cognitive impairment.

          -  The presence of hepatic or renal disease.

          -  The presence of other rheumatic and connective tissue disorders.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>hager omar m siddik</last_name>
    <role>Principal Investigator</role>
    <affiliation>teaching assistant at faculty of pharmacy ain shams university</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Facuty of Pharmacu Ain Shams University</name>
      <address>
        <city>Cairo</city>
        <state>Abasiya</state>
        <zip>11566</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>November 4, 2018</study_first_submitted>
  <study_first_submitted_qc>November 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2018</study_first_posted>
  <last_update_submitted>January 8, 2020</last_update_submitted>
  <last_update_submitted_qc>January 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>hager omar mohammed siddik</investigator_full_name>
    <investigator_title>Teaching assistant at clinical pharmacy department at faculty of pharmacy ain shams university</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

